Clinical Trial List
The Angeles Clinic and Research Institute is currently enrolling participants in clinical trials for:
Basal Cell Carcinoma
GDC-0449 - A Single-Arm, Open-Label, Expanded Access Study of GDC-0449 in Patients with Locally Advanced or Metastatic Basal Cell Carcinoma
Go back to the top
Brain Tumors
Coming soon...
Go back to the top
Breast Cancer
D-CARE - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients with Advanced GPNMB-expressing Breast Cancer
T-DM-1 - Phase III, Randomized, Multicenter, International, Two-arm, Open-Label Clinical Trial Designed to Compare the Safety and Efficacy of T-DM1 With That of Capecitabine + Lapatinib for HER2-Positive Unresectable, Locally Advanced Breast Cancer or Metastatic Breast Cancer
Go back to the top
Lung Cancer
NRAS/BRAF - A Phase 1 Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations
Go back to the top
Melanoma
Adjuvant Therapy
ECOG 1609 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma
Melanoma - First Line Therapy
ONTAK - A Phase II Open-Label, Multicenter Study of ONTAK in Patients with Stage IIIC and Stage IV Melanoma
IND.202 - A Randomized Phase II Study of Interleukin-21 (rIL-21) Versus Decarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma
ALTOR - A Phase Ib/II Study of ALT-801 with Cisplatin in Patients with Metastatic Melanoma
Melanoma – Pretreated/Any Line
BRAF - An Open-Label, Multicenter, Phase II, Study of Continuous Oral Vemurafenib in Patients With Metastatic Melanoma and BRAF Mutation Not Detected By Cobas® 4800 BRAF V600 Mutation Test
BRAF/MEK - An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination with the MEK Inhibitor GSK1120212 in Subjects with BRAF Mutant Metastatic Melanoma
NRAS/BRAF - A Phase 1 Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations
MLN4924 - A Phase I, Open-Label, Dose-Escalation Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Melanoma
MORAb-004 - A Study of the Efficacy and PK/PD Relationship of Monotherapy MORAb-004 in Subjects with Metastatic Melanoma
PD1 Antibody - Phase I Study of Single Agent MK-3475 in Patients with Progressive Locally Advanced or Metastatic Carcinomas and Melanoma
PD-L1 Antibody - A Phase I, Open-Label, Multicenter, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumor
A Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
A Phase I, Open Label Study of Ad-RTS-hIL-12, an Adenovirus Vector Engineered to Express hIL-12, in Combination with an Oral Activator Ligand, in Subjects with Unresectable Stage III or IV Melanoma
A Phase 1b Open Label, Single Arm, Multicenter Trial to Evaluate the Safety, Tolerance, Response Rate and Immunological Effects of Repeated Intratumoral Injections of Adenoviral Transduced Autologous Dendritic Cells Engineered to Express hIL-12 (INXN-3001) in Response to an Oral Activator Ligand Administered in Intra-Patient Escalating Doses in Patients with Unresectable Stage III C or IV Malignant Melanoma
Melanoma - Brain Metastasis
BRAF - An Open-Label, Single-Arm, Phase II, Multicenter Study to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Go back to the top
Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Taxane-based Therapy
Go back to the top
Phase I / Any Tumor
A Phase 1 Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects with Solid Tumors
A Phase I, Open-Label, Multicenter, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Non-hematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 (cmet inhibitor) in Adult Subjects with Advanced Solid Tumors
Colorectal Cancer
BRAF/MEK - An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination with the MEK Inhibitor GSK1120212 in Subjects with BRAF Mutant Metastatic Melanoma
NRAS/BRAF - A Phase 1 Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations
Pancreatic Cancer
Gastointestinal Cancer
Go back to the top
Clinical Trial List
The Angeles Clinic and Research Institute is currently enrolling participants in clinical trials for:
Basal Cell Carcinoma
GDC-0449 - A Single-Arm, Open-Label, Expanded Access Study of GDC-0449 in Patients with Locally Advanced or Metastatic Basal Cell Carcinoma
Go back to the top
Brain Tumors
Coming soon...
Go back to the top
Breast Cancer
D-CARE - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients with Advanced GPNMB-expressing Breast Cancer
T-DM-1 - Phase III, Randomized, Multicenter, International, Two-arm, Open-Label Clinical Trial Designed to Compare the Safety and Efficacy of T-DM1 With That of Capecitabine + Lapatinib for HER2-Positive Unresectable, Locally Advanced Breast Cancer or Metastatic Breast Cancer
Go back to the top
Lung Cancer
NRAS/BRAF - A Phase 1 Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations
Go back to the top
Melanoma
Adjuvant Therapy
ECOG 1609 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma
Melanoma - First Line Therapy
ONTAK - A Phase II Open-Label, Multicenter Study of ONTAK in Patients with Stage IIIC and Stage IV Melanoma
IND.202 - A Randomized Phase II Study of Interleukin-21 (rIL-21) Versus Decarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma
ALTOR - A Phase Ib/II Study of ALT-801 with Cisplatin in Patients with Metastatic Melanoma
Melanoma – Pretreated/Any Line
BRAF - An Open-Label, Multicenter, Phase II, Study of Continuous Oral Vemurafenib in Patients With Metastatic Melanoma and BRAF Mutation Not Detected By Cobas® 4800 BRAF V600 Mutation Test
BRAF/MEK - An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination with the MEK Inhibitor GSK1120212 in Subjects with BRAF Mutant Metastatic Melanoma
NRAS/BRAF - A Phase 1 Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations
MLN4924 - A Phase I, Open-Label, Dose-Escalation Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Melanoma
MORAb-004 - A Study of the Efficacy and PK/PD Relationship of Monotherapy MORAb-004 in Subjects with Metastatic Melanoma
PD1 Antibody - Phase I Study of Single Agent MK-3475 in Patients with Progressive Locally Advanced or Metastatic Carcinomas and Melanoma
PD-L1 Antibody - A Phase I, Open-Label, Multicenter, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumor
A Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
A Phase I, Open Label Study of Ad-RTS-hIL-12, an Adenovirus Vector Engineered to Express hIL-12, in Combination with an Oral Activator Ligand, in Subjects with Unresectable Stage III or IV Melanoma
A Phase 1b Open Label, Single Arm, Multicenter Trial to Evaluate the Safety, Tolerance, Response Rate and Immunological Effects of Repeated Intratumoral Injections of Adenoviral Transduced Autologous Dendritic Cells Engineered to Express hIL-12 (INXN-3001) in Response to an Oral Activator Ligand Administered in Intra-Patient Escalating Doses in Patients with Unresectable Stage III C or IV Malignant Melanoma
Melanoma - Brain Metastasis
BRAF - An Open-Label, Single-Arm, Phase II, Multicenter Study to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Go back to the top
Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Taxane-based Therapy
Go back to the top
Phase I / Any Tumor
A Phase 1 Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects with Solid Tumors
A Phase I, Open-Label, Multicenter, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Non-hematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 (cmet inhibitor) in Adult Subjects with Advanced Solid Tumors
Colorectal Cancer
BRAF/MEK - An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination with the MEK Inhibitor GSK1120212 in Subjects with BRAF Mutant Metastatic Melanoma
NRAS/BRAF - A Phase 1 Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations
Pancreatic Cancer
Gastointestinal Cancer
Go back to the top